The use of Chk1 and PARP1 inhibitors have been shown to radiosensitize p53 mutant pancreatic cells and the ATM kinase inhibitor KU-60019 preferentially sensitized p53-mutant glioma in vivo [108]. This evidence concerns the gene TP53 and central nervous system cancer.